Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

»ïÂ÷½Å°æÅëÀÇ ÀÓ»ó ¼Ò°ß°ú ¾à¹° Ä¡·á¿¡ °üÇÑ ¿¬±¸

A Study on Clinical Features and Pharmacologic Treatment Outcomes of Patients with Trigeminal Neuralgia

´ëÇѱ¸°­³»°úÇÐȸÁö 2009³â 34±Ç 2È£ p.207 ~ 216
°íÀ¯Á¤, ±è±Õ¿ä, ÇãÀ±°æ, ÃÖÀç°©,
¼Ò¼Ó »ó¼¼Á¤º¸
°íÀ¯Á¤ ( Ko Yu-Jeong ) - °æºÏ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
±è±Õ¿ä ( Kim Kyun-Yo ) - °æºÏ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
ÇãÀ±°æ ( Hur Yun-Kyung ) - °æºÏ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
ÃÖÀç°© ( Choi Jae-Kap ) - °æºÏ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç

Abstract

2003³âºÎÅÍ 2008³â±îÁö °æºÏ´ëÇб³º´¿ø ±¸°­³»°ú¸¦ ³»¿øÇÑ »ïÂ÷½Å°æÅë ȯÀÚ 90¸íÀÇ ÀÓ»ó ¼Ò°ß ¹× ¾à¹° Ä¡·á¿¡ ´ëÇÑ °á°ú¸¦ ºÐ¼®ÇÏ¿© ´ÙÀ½°ú °°Àº °á·ÐÀ» ¾ò¾ú´Ù.
1. »ïÂ÷½Å°æÅë ȯÀÚ´Â 40´ë ÀÌ»óÀÌ 94.4%¸¦ Â÷ÁöÇÏ¿´°í ³²³àºñ°¡ 1:2.1·Î ¿©¼º¿¡¼­ °ÅÀÇ 2¹è Á¤µµ È£¹ßÇÏ¿´´Ù.
2. »ïÂ÷½Å°æÀÇ »ó¾ÇºÐÁö¿¡ ´Üµ¶À¸·Î ÀÌȯµÈ °æ¿ì°¡ 51.1%·Î °¡Àå ¸¹¾Ò°í Á¿ìºñ°¡ 1:2.9·Î ¿ìÃø¿¡ ´õ ÀÚÁÖ ¹ß»ýÇÏ¿´´Ù.
3. 85¸í(94.4%)ÀÇ È¯ÀÚ°¡ °æºÏ´ëÇб³º´¿ø ±¸°­³»°ú¿¡ ³»¿øÇϱâ Àü »ïÂ÷½Å°æÅëÀ» Ä¡·áÇϱâ À§ÇØ ´Ù¸¥ ÀÇ·á±â°üÀ» ³»¿øÇÑ °æÇèÀÌ ÀÖ¾ú´Ù.
3. 40¸í(44.4%)ÀÇ È¯ÀÚ°¡ ÇöÀç Ä¡·á ÁßÀÎ Àü½ÅÁúȯÀ» °¡Áö°í ÀÖ¾ú´Ù.
4. Carbamazepine ´Üµ¶ Åõ¿©·Î 69¸í(76.7%)ÀÇ È¯ÀÚ°¡ È¿°ú¸¦ ³ªÅ¸³»¾úÀ¸¸ç ÀÌ ¶§ »ç¿ëµÈ CarbamazepineÀÇ ÀÏÀÏ ¿ë·®Àº Æò±Õ 402.9§·À̾ú´Ù. ¹Ý¸é¿¡ 16¸í(17.8%)ÀÇ È¯ÀÚ´Â Carbamazepine°ú ´Ù¸¥ ¾à¹°À» º¹ÇÕ Åõ¿©ÇÏ¿© È¿°ú¸¦ ³ªÅ¸³»¾ú°í »ç¿ëµÈ Carbamazepine ÀÏÀÏ ¿ë·®Àº Æò±Õ 618.8mgÀ̾úÀ¸¸ç °¡Àå ¸¹ÀÌ »ç¿ëµÈ º´¿ë ¾à¹°Àº BaclofenÀ̾ú´Ù. ³ª¸ÓÁö 5¸í(5.6%)ÀÇ È¯ÀÚ´Â CarbamazepineÀ¸·Î È¿°ú¸¦ ¾òÁö ¸øÇß´Ù.
5. Carbamazepine ´Üµ¶ Åõ¿©¿¡ È¿°ú°¡ ÀÖ¾ú´ø 69¸í Áß 39¸íÀº ³»¿ø ±â°£ µ¿¾È Áö¼ÓÀûÀÎ È¿°ú¸¦ ³ªÅ¸³»¾úÀ¸³ª 30¸íÀº Carbamazepine¿¡ ´ëÇÑ È¿°ú°¡ °¨¼ÒÇÏ¿´°Å³ª ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ º¹ÇÕ Åõ¾àÀ» ½ÃÇàÇÏ¿´°Å³ª ´Ù¸¥ ¾à¹°·Î ±³Ã¼ ¶Ç´Â ½Å°æ¿Ü°ú·Î ÀÇ·ÚÇÏ¿´´Ù.
6. 54¸í(60%)ÀÇ È¯ÀÚ¿¡¼­ Carbamazepine Åõ¿© ÈÄ Çö±âÁõ, Á¹À½, ¿À½É, Ç÷±¸ °¨¼Ò, ÇǺΠ¹ßÁø µîÀÇ ºÎÀÛ¿ëÀÌ ¹ß»ýÇÏ¿´À¸³ª ´ëºÎºÐ ±× Á¤µµ°¡ ¹Ì¾àÇϰųª ÀϽÃÀûÀ̾ú°í 11¸íÀÇ È¯ÀÚ°¡ ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ Carbaamzepien Åõ¾àÀ» Áß´ÜÇÏ¿´´Ù.

Trigeminal neuralgia is defined "a sudden, usually unilateral, severe, brief, stabbing, recurrent pain in the distribution of one or more branches of the fifth cranial nerve".
The initial treatment of choice for trigeminal neuralgia is medical therapy. In patients with medically intractable pain or intolerable medication side effects, invasive therapeutic approaches are often necessary.
Based on the amount of evidence and estimated efficacy, carbamazepine is the drug of choice in the management of trigeminal neuralgia. In case of insufficient or no response to carbamazepine, second-line drugs can be added.
In this study, the author tried to review and analyzed the cases of 90 patients whom had visited for treatment of trigeminal neuralgia at the Department of Oral Medicine, Kyungpook National University Hospital from 2003 to 2008.
The results were as follows:
1. Trigeminal neuralgia was significantly more common with advancing age, and nearly twice as common in women than men (ratio of 2.1:1)
2. The maxillary branch of the trigeminal nerve involved most often (51.1%), and the right side of the face is affected more commonly than the left (ratio of 2.9:1).
3. 85(94.4%) patients had experiences visiting medical or dental specialties before being referred to the Department of Oral Medicine.
4. 40(44.4%) patients with trigeminal neuralgia had systemic diseases.
5. Treatment with carbamazepine monotherapy was satisfactory initially in 69(76.7%) the patients, and the mean daily dose of carbamazepine was 402.9mg. On the other hand, 16(17.8%) patients expressed effectiveness after combination therapy of carbamazepine and other drugs.
6. Of the 69 patients who had a good initial response to carbamazepine monotherapy, 18 patients became resistant, so that combination therapy of carbamazepine and other drugs were necessary.
7. 54(60%) patients developed side effects such as dizziness, drowsiness, nausea, vomiting, blood dyscrasias, skin rash and constipation, and 11 of the patients decided to stop tmedicaion due to side effects.

Å°¿öµå

»ïÂ÷½Å°æÅë;ÀÓ»ó¼Ò°ß
Carbamazepine;Trigeminal neuralgia;Clinical features

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI